Good Life Advisors LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Good Life Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 31,624 shares of the biopharmaceutical company’s stock after buying an additional 1,468 shares during the period. Good Life Advisors LLC’s holdings in Pfizer were worth $910,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Worth Asset Management LLC purchased a new position in Pfizer in the first quarter worth $29,000. Briaud Financial Planning Inc purchased a new position in Pfizer in the third quarter worth $30,000. GoalVest Advisory LLC boosted its position in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the third quarter worth $34,000. Finally, VisionPoint Advisory Group LLC boosted its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

NYSE PFE traded down $0.03 during trading on Thursday, hitting $27.75. 39,669,508 shares of the company’s stock traded hands, compared to its average volume of 43,829,785. The stock has a fifty day moving average of $27.47 and a two-hundred day moving average of $29.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $42.22. The firm has a market cap of $157.14 billion, a P/E ratio of 77.25, a PEG ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. UBS Group lowered their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Barclays lowered their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.